MorphoSys Presents New Long-Term Data from L-MIND Suggesting

BOSTON - MorphoSys USA, Inc., a fully owned subsidiary of MorphoSys AG , announced data from the ongoing L-MIND study showing that Monjuvi plus lenalidomide followed by Monjuvi monotherapy provided... | September 29, 2022

Related Keywords

Germany , United States , United Kingdom , Texas , Planegg , Bayern , Massachusetts , Boston , Houston , Canada , Kaitlyn Nealy , Thomas Biegi , Johannes Duell , Julia Neugebauer , Development Officer , Linkedin , Xencor Inc , Twitter , Drug Administration , Nasdaq , Us Communications , Exchange Commission , University Hospital Wuerzburg Medical Clinic , Morphosys United States Inc , Society Of Hematologic Oncology , Sys United States , Tenth Annual Meeting , Hematologic Oncology , Sys Chief Research , Hospital Wuerzburg Medical Clinic , Antibody Dependent Cell Mediated Cytotoxicity , Antibody Dependent Cellular Phagocytosis , Medication Guide , Prescribing Information , Patient Information , Important Safety , News Publishing , Xencor , Nc Stock Exchange , News , Information , Press Release , Morphosys , Bully , Wned , Ubsidiary , F , G , Nnounced , Data , Rom , The , Ngoing , Study , Showing , Hat , Monjuvi , Plus , Lenalidomide , Ollowed , Y , Onotherapy Xncr Us98401f1057 ,